Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Ischaemic Stroke (AMASCIS-02): A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial Protocol

Investigators developed a Phase IIb, multicentre, randomized, double-blind, placebo-controlled clinical trial protocol to evaluate the safety and efficacy of intravenous administration of allogeneic adipose tissue-derived MSCs in patients with acute ischaemic stroke, concurrently with conventional stroke treatment.